Security Snapshot

ISHARES TR - U.S. PHARMA ETF (IHE) Institutional Ownership

CUSIP: 464288836

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

196

Shares (Excl. Options)

7,604,564

Price

$86.68

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+1,170,437
Value change
+$101,175,823
Number of holders
196
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported price per share
$92.61
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • IHE - ISHARES TR - U.S. PHARMA ETF is tracked under CUSIP 464288836.
  • 196 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 179 to 196 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $550,147,201 to $657,997,471.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 196 institutions filings for Q1 2026.

Open SEC evidence

Security key

464288836

Latest holder period

Q1 2026

13F holders

196

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 196 institutional investors reported holding 7,604,564 shares of ISHARES TR - U.S. PHARMA ETF (IHE).

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 7,604,564 $657,997,471 +$101,175,823 $86.68 196
2025 Q4 6,485,331 $550,147,201 +$150,318,415 $84.83 179
2025 Q3 4,719,905 $342,421,380 -$13,835,896 $72.56 150
2025 Q2 4,968,369 $325,628,195 -$8,276,835 $65.54 140
2025 Q1 4,897,901 $345,371,935 -$39,000,021 $70.56 151
2024 Q4 5,467,783 $359,359,917 +$8,463,665 $65.72 156
2024 Q3 5,298,041 $374,021,462 -$36,539,203 $70.61 144
2024 Q2 5,831,524 $386,871,861 +$20,429,427 $66.32 143
2024 Q1 5,585,305 $378,308,781 +$224,982,917 $67.90 140
2023 Q4 2,092,523 $386,524,330 +$264,647,538 $185.40 137
2023 Q3 618,504 $109,495,602 -$4,592,717 $176.98 126
2023 Q2 645,577 $115,762,827 -$10,083,284 $179.11 118
2023 Q1 734,313 $129,088,785 -$4,630,135 $175.28 127
2022 Q4 747,188 $138,995,470 +$9,168,861 $186.13 127
2022 Q3 692,535 $117,426,900 -$7,415,939 $169.54 109
2022 Q2 747,328 $143,356,273 +$33,526,994 $191.65 120
2022 Q1 572,187 $111,243,777 +$8,958,655 $194.25 118
2021 Q4 521,386 $104,202,203 -$3,381,738 $199.66 107
2021 Q3 536,082 $98,232,493 +$981,063 $183.14 107
2021 Q2 529,598 $98,372,552 +$6,457,088 $185.74 99
2021 Q1 494,862 $87,906,779 -$2,280,688 $177.66 99
2020 Q4 506,968 $90,990,918 +$3,797,914 $179.44 98
2020 Q3 486,383 $79,572,611 -$9,004,469 $163.53 92
2020 Q2 544,377 $83,775,755 +$14,643,808 $153.87 89
2020 Q1 452,102 $60,854,809 -$20,553,537 $134.58 92
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .